<International Circulation>:   You mentioned CRP do you think surrogate biomarkers like these have any application in terms of real clinical practice?
    Professor Ralph Brindis:  We are certainly learning a lot from these surrogate biomarkers. We heard a terrific talk today which highlighted the advantages and disadvantages on the use of these biomarkers to assess the efficacy of medication in other words how they can help us but also in some respects mislead us. So， we must put these biomarkers in proper context of clinical trials looking at outcomes to appreciate their tr